Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
30 results about "TNF inhibitor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A TNF inhibitor is a pharmaceutical drug that suppresses the physiologic response to tumor necrosis factor (TNF), which is part of the inflammatory response. TNF is involved in autoimmune and immune-mediated disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriasis, hidradenitis suppurativa and refractory asthma, so TNF inhibitors may be used in their treatment. The important side effects of TNF inhibitors include lymphomas, infections (especially reactivation of latent tuberculosis), congestive heart failure, demyelinating disease, a lupus-like syndrome, induction of auto-antibodies, injection site reactions, and systemic side effects.
Multiple-variable dose regimen for treating TNFalpha-related disorders
ActiveUS20060009385A1Reduce decreaseIncrease the areaBiocideOrganic active ingredientsDosing regimenRegimen
Multiple-variable dose methods for treating TNFα-related disorders, including Crohn's disease and psoriasis, comprising administering TNFα inhibitors, including TNFα antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
Owner:ABBVIE BIOTECHNOLOGY LTD
Multiple-variable dose regimen for treating TNFa-related disorders
InactiveUS20090304682A1Reducing remissionReducing signOrganic active ingredientsPeptide/protein ingredientsDosing regimenRegimen
Owner:ABBVIE BIOTECHNOLOGY LTD
Method of treating blood disorders
InactiveUS20050106148A1Heavy metal active ingredientsPeptide/protein ingredientsDiseaseWhite blood cell
The invention relates to methods of treating a blood disorder in a mammal with an interleukin-1 (IL-1) inhibitor. The invention also relates to methods of treating a blood disorder in a mammal with an IL-1 inhibitor, a TNF inhibitor and an erythropoietin (EPO) receptor agonist. The invention also relates to compositions of an IL-1 inhibitor and compositions of an IL-1 inhibitor, a TNF inhibitor and an EPO receptor agonist.
Owner:AMGEN INC
Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
Compounds are disclosed having the general formula R1—X—R2, wherein R1 and R2 are biologically active groups, at least one of which is polypeptidic. X is a non-peptidic polymeric group. R1 and R2 may be the same or different. Preferred R1 and R2 groups are interleukin-1 receptor antagonist, 30 kDa TNF inhibitor, interleukin-2 receptors and CR1 and muteins thereof. Also included are site selectively modified interleukin-1 receptor antagonist and 30 kDa TNF inhibitor.
Owner:UNIV OF COLORADO THE REGENTS OF +1
Use of certain drugs for treating nerve root injury
The present invention relates to a method and a pharmaceutical composition for treatment of nerve disorders comprising administration of a therapeutically effective dosage of at least two substances selected from the group consisting of TNF inhibitors, IL-1 inhibitors, IL-6 inhibitors, IL-8 inhibitors, FAS inhibitors, FAS ligand inhibitors, and IFN-gamma inhibitors. Preferably, at least one of the substances is a TNF inhibitor.
Owner:SCIATICON
Method of treating anemia by administering IL-1ra
The invention relates to methods of treating a blood disorder in a mammal with an interleukin-1 (IL-1) inhibitor. The invention also relates to methods of treating a blood disorder in a mammal with an IL-1 inhibitor, a TNF inhibitor and an erythropoietin (EPO) receptor agonist. The invention also relates to compositions of an IL-1 inhibitor and compositions of an IL-1 inhibitor, a TNF inhibitor and an EPO receptor agonist.
Owner:AMGEN INC
Combination therapy with co-stimulatory factors
Methods for treating an inflammatory or an immune condition are described. Methods for treating an inflammatory or an immune condition with IL-1 inhibitors and an inhibitor of B cell or T cell activation are described. Methods for treating an inflammatory or an immune condition with TNF inhibitors and an inhibitor of B cell or T cell activation are described.
Owner:AMGEN INC
Use of certain drugs for treating nerve root injury
Owner:SCIATICON
Extracellular TNF inhibitors for treating CNS disorders
InactiveUS20050180974A1Minimize adverse effectsConvenient treatmentCompound screeningNervous disorderNervous systemInjury brain
Methods and devices to attenuate tumor necrosis factor (TNF) and other pro-inflammatory mediators in the CNS to treat neurological, neurodegenerative, neuropsychiatric disorders, and brain injury are described. More particularly, TNF blocking agents that target TNF-receptor interactions and the effects of downstream secreted cytokines associated with an inflammatory cascade are described. Such TNF blocking agents are administered directly to the brain by, for example, intraparenchymal administration, intracerebroventricular administration, or administration into a cerebral artery. Devices described include therapy delivery devices comprising a reservoir capable of housing a TNF blocking agent and a catheter operably coupled to the device and adapted to deliver the TNF blocking agent to a target site within a subject.
Owner:MEDTRONIC INC
Compounds as PDE IV and TNF-inhibitors
This invention is directed to a [di(ether or thioether)heteroaryl or fluoro substituted aryl] compound or an N-oxide thereof or a pharmaceutically acceptable salt thereof, which is useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF).Compounds within the scope of the present invention also inhibit cyclic AMP phosphodiesterase, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting cyclic AMP phosphodiesterase, such disease states including inflammatory and autoimmune diseases, in particular type IV cyclic AMP phosphodiesterase. The present invention is therefore directed to their pharmacological use for inhibiting TNF and / or cyclic AMP phosphodiesterase, pharmacological compositions comprising the compounds and methods for their preparation.
Owner:AVENTIS PHARMA LTD
Combination Therapy with Co-Stimulatory Factors
Methods for treating an inflammatory or an immune condition are described. Methods for treating an inflammatory or an immune condition with IL-1 inhibitors and an inhibitor of B cell or T cell activation are described. Methods for treating an inflammatory or an immune condition with TNF inhibitors and an inhibitor of B cell or T cell activation are described.
Owner:AMGEN INC
Primer group, application, product and method for detecting SNP (single nucleotide polymorphism) loci related to drug metabolism capacity of rheumatic immunological diseases
ActiveCN110551813AImprove accuracyShort detection cycleMicrobiological testing/measurementDNA/RNA fragmentationRheumatismUric acid
The invention provides a primer group, an application, a product and a method for detecting SNP (single nucleotide polymorphism) loci related to drug metabolism capacity of rheumatic immunological diseases, and relates to the technical field of biology. The primer group for detecting the SNP loci related to the drug metabolism capacity of the rheumatic immunological diseases can be used for detecting metabolism capacity of an immunosuppressor, metabolism capacity of an immunomodulator, metabolism capacity of an anti-inflammatory agent, metabolism capacity of a TNF inhibitor, metabolism capacity of a B cell regulator, metabolism capacity of an IL-6 inhibitor, metabolism capacity of a uric acid lowering agent and metabolism capacity of a uricosuric agent. The primer group is designed for main mutation sites related to common drug metabolism of the rheumatic immunological diseases, can realize specific detection for locus mutation related to common drug metabolism of the rheumatic immunological diseases, and can greatly shorten detection cycle and reduce detection cost.
Owner:JIANGSU SIMCERE MEDICAL DEVICE CO LTD +2
Treatment of a disease of the gastrointestinal tract with a TNF inhibitor
PendingCN110430801APeptide/protein ingredientsImmunoglobulins against cytokines/lymphokines/interferonsDiseaseGastrointestinal disorder
This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a TNF inhibitor.
Owner:BIORA THERAPEUTICS INC
Compounds as PDE IV and TNF-inhibitors
This invention is directed to a [di(ether or thioether)heteroaryl or fluoro substituted aryl] compound or an N-oxide thereof or a pharmaceutically acceptable salt thereof, which is useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF). Compounds within the scope of the present invention also inhibit cyclic AMP phosphodiesterase, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting cyclic AMP phosphodiesterase, such disease states including inflammatory and autoimmune diseases, in particular type IV cyclic AMP phosphodiesterase. The present invention is therefore directed to their pharmacological use for inhibiting TNF and / or cyclic AMP phosphodiesterase, pharmacological compositions comprising the compounds and methods for their preparation.
Owner:AVENTIS PHARMA LTD
Methods of treating psoriasis
InactiveUS20120142605A1Testing efficacyOrganic active ingredientsPeptide/protein ingredientsGlucocorticoidTopical preparation
The invention includes methods for treating patients having psoriasis and methods for testing the efficacy of such treatments. The methods include treating the patients with a TNF inhibitor plus a topical preparation containing a glucocorticoid.
Owner:AMGEN INC
Application of japonicone A in preparation of tumor necrosis factor (TNF) inhibitor drugs
InactiveCN102406637AHigh clinical application valueOrganic active ingredientsSkeletal disorderDiseaseStructural formula
The invention provides an application of japonicone A (chemical structural formula I) in preparation of tumor necrosis factor (TNF) inhibitor drugs. The japonicone A is inula japonica extract. In the invention, by adopting a reverse docking technology for virtual screening, the result shows that TNF-alpha is potential binding protein of the japonicone A; by adopting a BIACORE technology, the result shows that the japonicone A can be directly combined with TNF-alpha coupled on a chip, and can inhibit the combination of the TNF-alpha and the TNF-R (receptor) coupled on a sensor chip; and furthermore, an experiment confirms that the japonicone A can be directly combined with the TNF-alpha and can inhibit the interaction of the TNF-alpha and the TNF-R, thus the japonicone A can be used for preparing TNF inhibitor drugs. The drug provided by the invention is a pharmaceutical composition prepared from a medicinal carrier and the japonicone A used as an active ingredient. The pharmaceutical composition can be used for treating TNF-related diseases such as osteoarthropathy, asthma, bronchitis, allergic rhinitis and the like, thereby providing a new way for treating the diseases and obtaining greater clinical application values.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Inhibitor of mitogen protein kinase p38 and preparation method of inhibitor
InactiveCN102633715AInhibit synthesisCurativeOrganic active ingredientsOrganic chemistryDiseaseIn vivo
The invention discloses an inhibitor of mitogen protein kinase p38 as well as a preparation method and application of the inhibitor. The inhibitor is an amino nicotinamide compound or an amino pyrazinamide compound. The preparation method mainly comprises the following steps: nitrifying 6-hydroxyl nicotinic acid to generate 5-nitro-6-hydroxyl nicotinic acid; treating 5-nitro-6-hydroxyl nicotinic acid with phosphorus oxybromide so as to convert 5-nitro-6-hydroxyl nicotinic acid into 5-nitro-6-bromonicotinic acid; carrying out Suzuki coupling reaction on 5-nitro-6-bromonicotinic acid to generate 5-nitro-6-aryl nicotinic acid; reacting 5-nitro-6-aryl nicotinic acid with oxalyl chloride to obtain 5-nitro-6-aryl nicotinamide; and carrying out hydrogenation reduction on a nitro group to obtain 5-amino-6-aryl nicotinamide. According to the invention, the inhibitor of the mitogen protein kinase p38 is a small molecular inhibitor which can effectively inhibit the synthesis of in vivo TNF (tumor necrosis factor)-alpha, has the curative effect of a large molecular inhibitor on diseases, is low in production cost, can be orally taken so that a patient can conveniently use the inhibitor, has good practicability, and can generate good economic and social effects.
Owner:WUXI ALLNATURE BIOLOGICAL SCI & TECH CO LTD
Primer set, application, product and method for detecting related SNP sites of drug metabolism ability of rheumatic immune diseases
ActiveCN110551813BImprove accuracyShort detection cycleMicrobiological testing/measurementDNA/RNA fragmentationIMMUNE SUPPRESSANTSImmunomodulating Agent
Owner:JIANGSU SIMCERE MEDICAL DEVICE CO LTD +2
Methods of treating or selecting a treatment for a subject resistant to TNF inhibitor using a nlrp3 antagonist
Provided herein are methods of treating a subject that include administering a therapeutically effective amount of an NLPR3 antagonist or a pharmaceutically acceptable salt, solvate, or co-crystal thereof to a subject identified as having a cell that has an elevated level of NLRP3 inflammasome activity and / or expression as compared to a reference level. Provided herein are methods of treating a subject, methods of selecting a treatment for a subject, methods of selecting a subject for treatment, and methods of selecting a subject for participation in a clinical study that include the administration of a therapeutically effective amount of an NLRP3 antagonist. Also provided are methods of treating a subject having resistance to an anti-TNFalpha agent and methods of determining the efficacy of treatment with an anti-TNFalpha agent. Also provided are methods of treating a subject with a combination of an NLRP3 antagonist and an anti-TNFalpha agent.
Owner:NOVARTIS AG
Compounds as PDE IV and TNF Inhibitors
Owner:AVENTIS PHARMA LTD
Composition and Method for the Treatment of Alzheimer's Disease
A method for treating Alzheimer's Disease (AD) by administering an efficacious amount of artemisone. It is hypothesized that the treatment counters AD by inhibiting the production of the amyloid protein which has been implicated as a contributing factor to the onset of AD and the associated AD dementia and memory loss. Additionally, artemisone acts to reduce inflammation in the brain associated with AD by inhibiting tumor necrosis factor (TNF). Artemisone is a particularly useful AD treatment as it is able to cross the blood-brain barrier whereas many other TNF inhibitors are unable to do so. Artemisone may be administered via the following routes: subcutaneous, intravenous, intrathecal, intramuscular, intranasal, oral, transepidermal, parenteral, by inhalation, or intracerebroventricular.
Owner:PARSONSON PETER SHEPHERD
Methods and compositions for assessing predicting responsiveness to a TNF inhibitor
InactiveUS20170121774A1Microbiological testing/measurementDisease diagnosisOncologyTreatment regimen
Methods, systems (e.g., computer systems), compositions, and kits are provided for predicting whether an individual will respond to treatment with a TNF inhibitor, for determining a treatment regimen for an individual (e.g. a therapy that does or does not include administration of a TNF inhibitor), and for treating an individual. The subject methods include measuring an expression level of an RGS1 expression product and / or an expression level of an IL11 expression product in a biological sample from an individual. In some cases, the methods include a step of calculating a TNF inhibitor signature score from measured expression levels (e.g., calculating a geometric mean of the expression levels of an RGS1 expression product and an IL11 expression product). After comparing measured expression levels and / or a calculated TNF inhibitor signature score with a reference, one can predict whether an individual will respond to treatment with a TNF inhibitor.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Ptprs and proteoglycans in rheumatoid arthritis
Provided herein, inter alia, are pharmaceutical compositions methods thereof that include a first amount of a PTPRS de-clustering agent and a second amount of a TNF inhibitor or an IL-6 inhibitor in synergistic amounts. The synergistic combinations provide (a) amelioration of disease or one or more symptoms of disease or (b) delay of onset of disease or one or more symptoms of disease.
Owner:LA JOLLA INST FOR IMMUNOLOGY +1
METHOD OF TREATING ANEMIA BY ADMINISTERING IL 1ra
Owner:AMGEN INC
Inhibitor of mitogen protein kinase p38 and preparation method of inhibitor
InactiveCN102633715BInhibit synthesisCurativeOrganic active ingredientsOrganic chemistrySocial effectsIn vivo
The invention discloses an inhibitor of mitogen protein kinase p38 as well as a preparation method and application of the inhibitor. The inhibitor is an amino nicotinamide compound or an amino pyrazinamide compound. The preparation method mainly comprises the following steps: nitrifying 6-hydroxyl nicotinic acid to generate 5-nitro-6-hydroxyl nicotinic acid; treating 5-nitro-6-hydroxyl nicotinic acid with phosphorus oxybromide so as to convert 5-nitro-6-hydroxyl nicotinic acid into 5-nitro-6-bromonicotinic acid; carrying out Suzuki coupling reaction on 5-nitro-6-bromonicotinic acid to generate 5-nitro-6-aryl nicotinic acid; reacting 5-nitro-6-aryl nicotinic acid with oxalyl chloride to obtain 5-nitro-6-aryl nicotinamide; and carrying out hydrogenation reduction on a nitro group to obtain 5-amino-6-aryl nicotinamide. According to the invention, the inhibitor of the mitogen protein kinase p38 is a small molecular inhibitor which can effectively inhibit the synthesis of in vivo TNF (tumor necrosis factor)-alpha, has the curative effect of a large molecular inhibitor on diseases, is low in production cost, can be orally taken so that a patient can conveniently use the inhibitor, has good practicability, and can generate good economic and social effects.
Owner:WUXI ALLNATURE BIOLOGICAL SCI & TECH CO LTD
Compositions and methods for treating cancer
ActiveUS20190255050A1Rapid increase in TNF levelSuppresses TNF mRNA levelOrganic active ingredientsPeptide/protein ingredientsOncologyEGFR inhibitors
Provided herein are methods and pharmaceutical compositions for treating cancer, in a patient in need thereof, said method comprising administering to said patient an effective amount of an EGFR inhibitor and a TNF inhibitor
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPT OF VETERANS AFFAIRS
Serum biomarkers for predicting and evaluating response to TNF inhibitor therapy in rheumatoid arthritis patients
ActiveUS20210215712A1Antibody mimetics/scaffoldsImmunoglobulins against cytokines/lymphokines/interferonsCXCL10CXCL13
The present disclosure is directed to methods and kits of use of serum biomarkers, including CXCL10, CXCL13, and / or sCD27, for predicting and evaluating therapeutic response to TNF inhibitor therapy in a patient in need thereof.
Owner:ROWAN UNIVERSITY
Combination Of Local And Systemic Therapies For Enhanced Treatment of Dermatologic Conditions
InactiveUS20220054449A1High activityImprove efficacyAntipyreticAerosol deliveryRetinoidAntiendomysial antibodies
A treatment for inflammatory dermatoses, such as psoriasis and atopic dermatitis (eczema), is disclosed that utilizes topical administration of a halogenated xanthene, such as rose bengal, together with administration of one or more complementary targeted systemic dermatology therapies, preferably a therapy that addresses the inflammatory pathway and is other than an NSAID that is a COX-1 and / or COX-2 inhibitor. Examples of complementary targeted systemic therapeutic ingredients include: corticosteroids, including betamethasone dipropionate and fluocinonide; dithranol; vitamin D analogs, including calcipotriol; and retinoids, non-biologics including methotrexate, ciclosporin, hydroxycarbamide, and fumarates including dimethyl fumarate; as well as one or more biologics, including antibodies or paratope-containing antibody portions to TNF-α, antibodies to pro-inflammatory cytokines interleukin-12, interleukin-23 and interleukin-17, and TNF inhibitors. Treatment of other epithelial tissue, such as the lining of the gut, is also disclosed.
Owner:THE ROCKEFELLER UNIV +1
Ptprs and proteoglycans in rheumatoid arthritis
PendingUS20210393740A1Reduce the amount of solutionHydrolasesPeptide/protein ingredientsDiseaseDepressant
Provided herein, inter alia, are pharmaceutical compositions methods thereof that include a first amount of a PTPRS de-clustering agent and a second amount of a TNF inhibitor or an IL-6 inhibitor in synergistic amounts. The synergistic combinations provide (a) amelioration of disease or one or more symptoms of disease or (b) delay of onset of disease or one or more symptoms of disease.
Owner:LA JOLLA INST FOR IMMUNOLOGY +1
Methods and compositions for treating cancer
ActiveUS11285154B2Inhibitory activityRapid responsePeptide/protein ingredientsImmunoglobulins against cytokines/lymphokines/interferonsPharmaceutical drugDepressant
Provided herein are methods and pharmaceutical compositions for treating cancer, in a patient in need thereof, said method comprising administering to said patient an effective amount of an EGFR inhibitor and a TNF inhibitor.
Owner:U S GOVERNMENT REPRESENTED BY THE DEPT OF VETERANS AFFAIRS
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com